Associated Genetic Biomarkers
B-cell neoplasms most frequently harbor alterations in KMT2D, CREBBP, TP53, BCL2, and CDKN2A .
KMT2D Mutation, CREBBP Mutation, TP53 Mutation, BCL2 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in B-cell neoplasm .
There are 7 clinical trials for B-cell neoplasm, of which 6 are open and 1 is completed or closed. Of the trials that contain B-cell neoplasm as an inclusion criterion, 5 are phase 1 (4 open) and 2 are phase 1/phase 2 (2 open).
MS4A1, CD19, and CD22 are the most frequent gene inclusion criteria for B-cell neoplasm clinical trials .
Cd19 chimeric antigen receptor t-cells, cd20 chimeric antigen recepter t-cells, and ly3039478 are the most common interventions in B-cell neoplasm clinical trials.
Significant Genes in B-Cell Neoplasm
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.